🟢 Cerenome is trading 6% up today after Florida Blue added coverage for both tests

Cerenome is trading at $1.90, up 5.87%, following its October 8 announcement of a Florida Blue in-network agreement covering both tests.

• The agreement adds approximately 6 million covered lives, bringing Cerenome’s contracted payer footprint to approximately 164 million.
• It establishes reimbursement for both tumor-cell enumeration and molecular profiling tests.
• Available coverage identifies no separate October 9 company announcement; trading-volume details were unavailable.